RB1 is altered in 9.42% of malignant glioma patients [4].

RB1 Expression is an inclusion criterion in 5 clinical trials for malignant glioma, of which 4 are open and 1 is closed. Of the trials that contain RB1 Expression and malignant glioma as inclusion criteria, 3 are early phase 1 (3 open) and 2 are phase 1 (1 open) [5].

RB1 is altered in 3.68% of breast carcinoma patients [4].

RB1 Expression is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain RB1 Expression and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [5].

RB1 is altered in 5.49% of malignant solid tumor patients [4].

RB1 Expression is an inclusion criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain RB1 Expression and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (2 open) [5].

RB1 Expression is an inclusion criterion in 2 clinical trials for diffuse intrinsic pontine glioma, of which 1 is open and 1 is closed. Of the trials that contain RB1 Expression and diffuse intrinsic pontine glioma as inclusion criteria, 2 are phase 1 (1 open) [5].

RB1 is altered in 1.59% of fallopian tube carcinoma patients [4].

RB1 Expression is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RB1 Expression and fallopian tube carcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

RB1 is altered in 7.01% of glioma patients [4].

RB1 Expression is an inclusion criterion in 2 clinical trials for glioma, of which 1 is open and 1 is closed. Of the trials that contain RB1 Expression and glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

RB1 is altered in 3.98% of hepatocellular carcinoma patients [4].

RB1 Expression is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RB1 Expression and hepatocellular carcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

RB1 is altered in 33.43% of leiomyosarcoma patients [4].

RB1 Expression is an inclusion criterion in 2 clinical trials for leiomyosarcoma, of which 2 are open and 0 are closed. Of the trials that contain RB1 Expression and leiomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

RB1 is altered in 2.98% of non-hodgkin lymphoma patients [4].

RB1 Expression is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain RB1 Expression and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

RB1 is altered in 4.03% of ovarian carcinoma patients [4].

RB1 Expression is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RB1 Expression and ovarian carcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

RB1 is altered in 4.35% of primary peritoneal carcinoma patients [4].

RB1 Expression is an inclusion criterion in 2 clinical trials for primary peritoneal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RB1 Expression and primary peritoneal carcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

RB1 is altered in 5.75% of prostate carcinoma patients [4].

RB1 Expression is an inclusion criterion in 2 clinical trials for prostate carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RB1 Expression and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [5].

RB1 is altered in 9.94% of soft tissue sarcoma patients [4].

RB1 Expression is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain RB1 Expression and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

RB1 is altered in 3.22% of anaplastic astrocytoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 Expression is an inclusion criterion in 1 clinical trial for angiosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and angiosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 Expression is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains RB1 Expression and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

RB1 is altered in 16.16% of bladder carcinoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Expression and bladder carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

RB1 is altered in 1.96% of central nervous system embryonal neoplasm patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for central nervous system embryonal neoplasm, of which 0 are open and 1 is closed. Of the trial that contains RB1 Expression and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (0 open) [5].

RB1 is altered in 5.9% of central nervous system neoplasm patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for central nervous system neoplasm, of which 0 are open and 1 is closed. Of the trial that contains RB1 Expression and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (0 open) [5].

RB1 is altered in 1.95% of chondrosarcoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

RB1 Expression is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and chordoma as inclusion criteria, 1 is phase 2 (1 open) [5].

RB1 is altered in 3.3% of colorectal carcinoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Expression and colorectal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

RB1 is altered in 6.25% of dedifferentiated chondrosarcoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

RB1 is altered in 0.83% of dedifferentiated liposarcoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for dedifferentiated liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and dedifferentiated liposarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

RB1 Expression is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 is altered in 3.08% of ductal carcinoma in situ patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for ductal carcinoma in situ, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and ductal carcinoma in situ as inclusion criteria, 1 is phase 2 (1 open) [5].

RB1 is altered in 6.5% of endometrial carcinoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and endometrial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

RB1 is altered in 1.28% of ependymoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for ependymoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Expression and ependymoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RB1 is altered in 2.08% of epithelioid sarcoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for epithelioid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and epithelioid sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 is altered in 4.08% of esophageal carcinoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Expression and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

RB1 is altered in 7.14% of fibrosarcoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for fibrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and fibrosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 is altered in 3.06% of gastric carcinoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Expression and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

RB1 is altered in 0.5% of germ cell tumor patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains RB1 Expression and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

RB1 is altered in 11.32% of glioblastoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 is altered in 0.75% of histiocytic and dendritic cell neoplasm patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

RB1 is altered in 3.76% of invasive breast carcinoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

RB1 is altered in 4.13% of liposarcoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and liposarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 is altered in 1.05% of malignant peripheral nerve sheath tumor patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 is altered in 2.72% of medulloblastoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Expression and medulloblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

RB1 is altered in 3.45% of melanoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

RB1 is altered in 1.53% of meningioma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [5].

RB1 is altered in 2.48% of multiple myeloma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Expression and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open) [5].

RB1 is altered in 12.12% of myxofibrosarcoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for myxofibrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and myxofibrosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 is altered in 10.38% of osteosarcoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

RB1 is altered in 25.0% of pleomorphic rhabdomyosarcoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for pleomorphic rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and pleomorphic rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 Expression is an inclusion criterion in 1 clinical trial for spinal cord neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and spinal cord neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 is altered in 3.17% of synovial sarcoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and synovial sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 Expression is an inclusion criterion in 1 clinical trial for undifferentiated (embryonal) sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and undifferentiated (embryonal) sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 is altered in 21.01% of undifferentiated pleomorphic sarcoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

RB1 is altered in 14.62% of urothelial carcinoma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 Expression and urothelial carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

RB1 is altered in 3.98% of WHO grade III glioma patients [4].

RB1 Expression is an inclusion criterion in 1 clinical trial for WHO grade III glioma, of which 1 is open and 0 are closed. Of the trial that contains RB1 Expression and WHO grade III glioma as inclusion criteria, 1 is phase 1 (1 open) [5].